CA2683032A1 - Formulations de docetaxel avec de l'acide lipoique et/ou de l'acide dihydrolipoique - Google Patents

Formulations de docetaxel avec de l'acide lipoique et/ou de l'acide dihydrolipoique Download PDF

Info

Publication number
CA2683032A1
CA2683032A1 CA2683032A CA2683032A CA2683032A1 CA 2683032 A1 CA2683032 A1 CA 2683032A1 CA 2683032 A CA2683032 A CA 2683032A CA 2683032 A CA2683032 A CA 2683032A CA 2683032 A1 CA2683032 A1 CA 2683032A1
Authority
CA
Canada
Prior art keywords
docetaxel
pharmaceutically acceptable
acceptable salt
free
lipoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2683032A
Other languages
English (en)
Inventor
Nageswara R. Palepu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scidose LLC
Original Assignee
Scidose LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scidose LLC filed Critical Scidose LLC
Priority to CA2683032A priority Critical patent/CA2683032A1/fr
Publication of CA2683032A1 publication Critical patent/CA2683032A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2683032A 2009-10-20 2009-10-20 Formulations de docetaxel avec de l'acide lipoique et/ou de l'acide dihydrolipoique Abandoned CA2683032A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2683032A CA2683032A1 (fr) 2009-10-20 2009-10-20 Formulations de docetaxel avec de l'acide lipoique et/ou de l'acide dihydrolipoique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2683032A CA2683032A1 (fr) 2009-10-20 2009-10-20 Formulations de docetaxel avec de l'acide lipoique et/ou de l'acide dihydrolipoique

Publications (1)

Publication Number Publication Date
CA2683032A1 true CA2683032A1 (fr) 2011-04-20

Family

ID=43896956

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2683032A Abandoned CA2683032A1 (fr) 2009-10-20 2009-10-20 Formulations de docetaxel avec de l'acide lipoique et/ou de l'acide dihydrolipoique

Country Status (1)

Country Link
CA (1) CA2683032A1 (fr)

Similar Documents

Publication Publication Date Title
US20080319048A1 (en) Solubilized formulation of docetaxel without tween 80
US20120065255A1 (en) Cabazitaxel formulations and methods of preparing thereof
AU2010308497A1 (en) Docetaxel formulations with lipoic acid
US20090118354A1 (en) Liquid Pharmaceutical Formulations of Docetaxel
US8912228B2 (en) Docetaxel formulations with lipoic acid
US8541465B2 (en) Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8476310B2 (en) Docetaxel formulations with lipoic acid
JP2011529930A (ja) 注射可能タキサン医薬品組成物
CA2683032A1 (fr) Formulations de docetaxel avec de l'acide lipoique et/ou de l'acide dihydrolipoique
CA3001526A1 (fr) Compositions de fulvestrant
US20110092579A1 (en) Solubilized formulation of docetaxel
US20180280295A1 (en) Single vial ready to use cabazitaxel formulations with increased stability and methods of preparations
US20240207217A1 (en) Improved treatment methods for cabazitaxel
CA2683248A1 (fr) Formulation solubilisee de docetaxel
EP4025205A1 (fr) Formulations liquides de cabazitaxel
AU2006257718A1 (en) Liquid pharmaceutical formulations of docetaxel
WO2018109731A1 (fr) Compositions pharmaceutiques de taxane et de ses dérivés

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20121022